

A genomewide scan for common alleles affecting risk for autism

Richard Anney¹, Lambertus Klei², Dalila Pinto³, Regina Regan⁴, Judith Conroy⁴, Tiago R. Magalhaes^{5,6}, Catarina Correia^{5,6}, Brett S. Abrahams⁷, Nuala Sykes⁸, Alistair T. Pagnamenta⁸, Joana Almeida⁹, Elena Bacchelli¹⁰, Anthony J. Bailey^{11§}, Gillian Baird¹², Agatino Battaglia^{13§}, Tom Berney¹⁴, Nadia Bolshakova¹, Sven Bölte¹⁵, Patrick F. Bolton¹⁶, Thomas Bourgeron¹⁷, Sean Brennan¹, Jessica Brian¹⁸, Andrew R. Carson³, Guillermo Casallo³, Jillian Casey⁴, Su Hee Chu², Lynne Cochrane¹, Christina Corsello¹⁹, Emily L. Crawford²⁰, Andrew Crossett²¹, Geraldine Dawson^{22,23§}, Maretha de Jonge²⁴, Richard Delorme²⁵, Irene Drmic¹⁸, Eftichia Duketis¹⁵, Frederico Duque⁹, Annette Estes²⁶, Penny Farrar⁸, Bridget A. Fernandez²⁷, Susan E. Folstein²⁸, Eric Fombonne²⁹, Christine M. Freitag^{15§}, John Gilbert²⁸, Christopher Gillberg³⁰, Joseph T. Glessner³¹, Jeremy Goldberg³², Andrew Green^{5,6}, Jonathan Green³³, Stephen J. Guter³⁴, Hakon Hakonarson^{31,35§}, Elizabeth A. Heron¹, Matthew Hill¹, Richard Holt⁸, Jennifer L. Howe³, Gillian Hughes¹, Vanessa Hus¹⁹, Roberta Iglizoi¹³, Cecilia Kim³¹, Sabine M. Klauck^{36§}, Alexander Kolevzon³⁷, Olena Korvatska³⁸, Vlad Kustanovich³⁹, Clara M. Lajonchere³⁹, Janine A. Lamb⁴⁰, Magdalena Laskawiec¹¹, Marion Leboyer⁴¹, Ann Le Couteur¹⁴, Bennett L. Leventhal^{42,43}, Anath C. Lionel³, Xiao-Qing Liu³, Catherine Lord¹⁹, Linda Lotspeich⁴⁴, Sabata C. Lund²⁰, Elena Maestrini^{10§}, William Mahoney⁴⁴, Carine Mantoulan⁴⁵, Christian R. Marshall³, Helen McConachie¹⁴, Christopher J. McDougle⁴⁶, Jane McGrath¹, William M. McMahon^{47§}, Nadine M. Melhem², Alison Merikangas¹, Ohsuke Migita³, Nancy J. Minshew⁴⁸, Ghazala K. Mirza⁸, Jeff Munson⁴⁹, Stanley F. Nelson^{50§}, Carolyn Noakes¹⁸, Abdul Noor⁵¹, Gudrun Nygren³⁰, Guiomar Oliveira^{9§}, Katerina Papanikolaou⁵², Jeremy R. Parr⁵³, Barbara Parrini¹³, Tara Paton³, Andrew Pickles⁵⁴, Joseph Piven^{55§}, David J Posey⁴⁶, Annemarie Poustka^{36,X}, Fritz Poustka¹⁵, Aparna Prasad³, Jiannis Ragoussis⁸, Katy Renshaw¹¹, Jessica Rickaby³, Wendy Roberts¹⁸, Kathryn Roeder²¹, Bernadette Roge⁵⁶, Michael L. Rutter⁵⁷, Laura J. Bierut⁵⁸, John P. Rice⁵⁸, Jeff Salt³⁴, Katherine Sansom³, Daisuke Sato³, Ricardo Segurado¹, Lili Senman¹⁸, Naisha Shah⁴, Val C. Sheffield⁵⁹, Latha Soorya³⁷, Inês Sousa⁸, Vera Stoppioni⁶⁰, Christina Strawbridge³², Raffaella Tancredi¹³, Katherine Tansey¹, Bhooma Thiruvahindrapduram³, Ann P. Thompson³², Susanne Thomson²⁰, Ana Tryfon³⁷, John Tsiantis⁵², Herman Van Engeland²⁴, John B. Vincent⁶¹, Fred Volkmar⁶¹, Simon Wallace¹¹, Kai Wang³¹, Zhouzhi Wang¹, Thomas H. Wassink^{62§}, Kirsty Wing⁸, Kerstin Wittmeyer⁵⁶, Shawn Wood², Brian L. Yaspan²⁰, Danielle Zurawiecki³⁷, Lonnie Zwaigenbaum⁶³, Catalina Betancur^{64§}, Joseph D. Buxbaum^{37§}, Rita M. Cantor^{50§}, Edwin H. Cook^{34§}, Hilary Coon^{47§}, Michael L. Cuccaro²⁸, Louise Gallagher^{1§}, Daniel H. Geschwind^{7§}, Michael Gill^{1§}, Jonathan L. Haines^{65§}, Judith Miller⁴⁷, Anthony P. Monaco^{8§}, John I. Nurnberger Jr.^{46§}, Andrew D. Paterson^{3§}, Margaret A. Pericak-Vance^{28§}, Gerard D. Schellenberg^{66§}, Stephen W. Scherer^{3§}, James S. Sutcliffe^{20§}, Peter Szatmari^{32§}, Astrid M. Vicente^{5,6§}, Veronica J. Vieland^{67§}, Ellen M. Wijsman^{68§}, Bernie Devlin^{28*}, Sean Ennis^{4§}, Joachim Hallmayer^{44§}

¹Autism Genetics Group, Department of Psychiatry, School of Medicine, Trinity College Dublin 8, Ireland. ²Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, 15232, USA. ³The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children and Department of Molecular Genetics, University of Toronto, Ontario, M5G 1L7, Canada. ⁴School of Medicine and Medical Science University College, Dublin 4, Ireland. ⁵Instituto Nacional de Saude Dr Ricardo Jorge and Instituto Gulbenkian de Ciência, 1649-016 Lisbon, Portugal. ⁶BioFIG - Center for Biodiversity, Functional & Integrative Genomics, Campus da FCUL, C2.2.12, Campo Grande, 1749-016 Lisboa, Portugal. ⁷Department of Neurology, University of California - Los Angeles School of Medicine, Los Angeles, California 90095, USA. ⁸Wellcome Trust Centre for Human Genetics, University of Oxford, OX3 7BN, UK. ⁹Hospital Pediátrico de Coimbra, 3000 – 076 Coimbra, Portugal. ¹⁰Department of Biology, University of Bologna, 40126 Bologna, Italy. ¹¹Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, OX3 7JX, UK. ¹²Newcomen Centre, Guy's Hospital, London, SE1 9RT, UK. ¹³Stella Maris Institute for Child and Adolescent Neuropsychiatry, 56128 Calambrone (Pisa), Italy. ¹⁴Child and Adolescent Mental Health, University of Newcastle, Sir James Spence Institute, Newcastle upon Tyne, NE1 4LP, UK. ¹⁵Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, J.W. Goethe University Frankfurt, 60528 Frankfurt, Germany. ¹⁶Department of Child and Adolescent Psychiatry, Institute of Psychiatry, London, SE5 8AF, UK. ¹⁷Human Genetics and Cognitive Functions, Institut Pasteur; University Paris Diderot-Paris 7, CNRS URA 2182, Fondation FondaMental, 75015 Paris, France. ¹⁸Autism Research Unit, The Hospital for Sick Children and Bloorview Kids Rehabilitation, University of Toronto, Toronto, Ontario, M5G 1Z8, Canada. ¹⁹Autism and Communicative Disorders Centre, University of Michigan, Ann Arbor, Michigan, 48109, USA. ²⁰Department of Molecular Physiology and Biophysics, Vanderbilt Kennedy Center, and Centers for Human Genetics Research and Molecular Neuroscience, Vanderbilt University, Nashville, Tennessee 37232, USA. ²¹Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA. ²²Autism Speaks, New York, New York, 10016, USA. ²³Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina, 27599, USA. ²⁴Department of Child Psychiatry, University Medical Center, Utrecht, 3508 GA, The Netherlands. ²⁵APHP, Hôpital Robert Debré, Child and Adolescent Psychiatry, 75019 Paris, France. ²⁶Department of Speech and Hearing Sciences, University of Washington, Seattle, Washington 98195, USA. ²⁷Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John's Newfoundland, A1B 3V6, Canada. ²⁸The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida 33101, USA. ²⁹Division of Psychiatry, McGill University, Montreal, Quebec, H3A 1A1, Canada. ³⁰Department of Child and Adolescent Psychiatry, Göteborg University Göteborg, S41345, Sweden. ³¹The Center for Applied Genomics, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. ³²Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, L8N 3Z5, Canada. ³³Academic Department of Child Psychiatry, Booth Hall of Children's Hospital, Blackley, Manchester, M9 7AA, UK. ³⁴Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, 60608, USA. ³⁵Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. ³⁶Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. ³⁷The Seaver Autism Center for Research and Treatment, Department of Psychiatry, Mount Sinai School of Medicine, New York 10029, USA. ³⁸Department of Medicine, University of Washington, Seattle,

Washington 98195, USA. ³⁹Autism Genetic Resource Exchange, Autism Speaks, Los Angeles, California 90036-4234, USA. ⁴⁰Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, M13 9PT, UK. ⁴¹INSERM U995, Department of Psychiatry, Groupe hospitalier Henri Mondor-Albert Chenevier, AP-HP; University Paris 12, Fondation FondaMental, Créteil, 94000, France. ⁴²Nathan Kline Institute for Psychiatric Research (NKI), 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. ⁴³Department of Child and Adolescent Psychiatry, New York University and NYU Child Study Center, 550 First Avenue, NY, NY 10016, USA. ⁴⁴Department of Psychiatry, Division of Child and Adolescent Psychiatry and Child Development, Stanford University School of Medicine, Stanford, California 94304, USA. ⁴⁵Department of Pediatrics, McMaster University, Hamilton, Ontario, L8N 3Z5, Canada. ⁴⁶Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. ⁴⁷Psychiatry Department, University of Utah Medical School, Salt Lake City, Utah 84108, USA. ⁴⁸Departments of Psychiatry and Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213. ⁴⁹Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, USA. ⁵⁰Department of Human Genetics, University of California - Los Angeles School of Medicine, Los Angeles, California 90095, USA. ⁵¹Centre for Addiction and Mental Health, Clarke Institute and Department of Psychiatry, University of Toronto, Toronto, Ontario M5G 1X8, Canada. ⁵²University Department of Child Psychiatry, Athens University, Medical School, Agia Sophia Children's Hospital, 115 27 Athens, Greece. ⁵³Institutes of Neuroscience and Health and Society, Newcastle University, Newcastle Upon Tyne, NE1 7RU, UK. ⁵⁴Department of Medicine, School of Epidemiology and Health Science, University of Manchester, Manchester, M13 9PT, UK. ⁵⁵Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, North Carolina 27599-3366, USA. ⁵⁶Centre d'Etudes et de Recherches en Psychopathologie, University de Toulouse Le Mirail, Toulouse 31200, France. ⁵⁷Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, London, SE5 8AF, UK. ⁵⁸Department of Psychiatry, Washington University in St. Louis, School of Medicine, St. Louis, Missouri 63130, USA. ⁵⁹Department of Pediatrics and Howard Hughes Medical Institute Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA. ⁶⁰Neuropsychiatria Infantile, Ospedale Santa Croce, 61032 Fano, Italy. ⁶¹Child Study Centre, Yale University, New Haven, Connecticut 06520, USA. ⁶²Department of Psychiatry, Carver College of Medicine, Iowa City, Iowa 52242, USA. ⁶³Department of Pediatrics, University of Alberta, Edmonton, Alberta T6G 2J3, Canada. ⁶⁴INSERM U952 and CNRS UMR 7224 and UPMC Univ Paris 06, Paris 75005, France. ⁶⁵Center for Human Genetics Research, Vanderbilt University Medical Centre, Nashville, Tennessee 37232, USA. ⁶⁶Pathology and Laboratory Medicine, University of Pennsylvania, Pennsylvania 19104, USA. ⁶⁷Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio 43205, USA. ⁶⁸Departments of Biostatistics and Medicine, University of Washington, Seattle, Washington 98195, USA.


[§]Lead AGP investigators who contributed equally to this project.

^x Deceased

*Correspondence should be addressed to Bernie Devlin, Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 O'Hara St., Pittsburgh, PA 15213.

e-mail: devlinbj@upmc.edu; phone: 412-246-6642; fax 412-246-6640.

Supplementary Figure 1. Results from ancestry analysis using genome-wide genotype data. Presented are the first and second eigenvectors from the spectral decomposition of the genotype data. Red maps to Europeans versus non-European (blue) ancestry. Letters correspond (roughly) to Northwestern Europe (a), Southern Europe (b), other European ancestry (c), African/African-American (d), Asian (e) and Latino (f).




Supplementary Table 1. Quality control (QC) steps for genome-wide association.

QC evaluation	Level for QC	Number with QC failure		Number	
		Families	Individuals	Families	Individuals
Starting count	None	0	0	1558	4712
Ambiguous gender	Family	9	--	-9	-28
Pedigree error	Individual	--	1	0	-1
Proband has probably damaging CNV	Family	80	--	-80	-240
Excess Mendelian errors	Family	19	--	-19	-58
Duplicates	Family	4		-4	-17
Not genotyped	Individual		37		-37
Genotype completion rate	Individual		27	-1	-27
Families without genotyped children	Family	24	--	-24	-40
Families with genotyped child but missing parents	Family	23		-23	-45
Failed to meet diagnostic criteria	Individual	--	34	-29	-92
Final count	None	0	0	1369 ¹	4127

¹) The breakdown of families was 1,369 total families; 1,353 nuclear families with one proband, 14 nuclear families with two probands, one family with cousins as probands, and one family with second cousins as probands (estimated from genetic data.)

Supplementary Figure 2. Manhattan plots for primary analyses.



Supplementary Figure 3. QQ plots of genome-wide association data from primary analyses.



Supplementary Table 2. Summary of top association signals from primary analyses across all primary analytic subgroups. Reporting restricted to SNPs that meet or fall below the association threshold of $P < 5 \times 10^{-6}$. Spc=spectrum, Str=strict, All=all ancestries, Eur=European ancestries.

SNP	Chr.	Position	Gene	MAF	Allele	Spc All			Str All			Spc Eur			Str Eur		
						OR	95%CI	P									
rs6731562	2	172506507	<i>HAT1</i>	0.34	G	1.23	1.08-1.41	6.00E-03	1.51	1.27-1.81	3.30E-05	1.33	1.15-1.54	4.50E-04	1.64	1.35-1.99	4.70E-06
rs10258862	7	39083322	<i>POU6F2</i>	0.33	G	1.41	1.23-1.61	3.70E-06	1.43	1.21-1.71	1.80E-04	1.43	1.25-1.65	5.10E-06	1.44	1.20-1.73	3.90E-04
rs6557675	8	23396490	-	0.31	A	0.72	0.63-0.82	8.70E-06	0.61	0.51-0.72	2.20E-07	0.74	0.64-0.85	1.20E-04	0.62	0.52-0.75	4.20E-06
rs4078417	14	50826631	-	0.34	C	1.38	1.21-1.57	1.90E-05	1.50	1.26-1.79	4.10E-05	1.43	1.25-1.64	4.80E-06	1.56	1.29-1.88	1.90E-05
rs7142002	14	101430497	<i>PPP2R5C</i>	0.06	G	0.60	0.47-0.77	3.30E-05	0.55	0.39-0.76	2.00E-04	0.54	0.41-0.70	1.90E-06	0.45	0.31-0.65	6.30E-06
rs17284809	16	15730300	<i>MYH11</i>	0.04	A	0.52	0.39-0.69	1.70E-06	0.53	0.36-0.76	2.60E-04	0.53	0.40-0.70	4.90E-06	0.55	0.37-0.79	7.20E-04
rs205409	16	27971448	<i>GSG1L</i>	0.43	G	0.72	0.64-0.82	9.60E-06	0.69	0.58-0.81	1.10E-04	0.69	0.60-0.79	1.10E-06	0.63	0.53-0.75	4.90E-06
rs4150167	16	82771184	<i>TAF1C</i>	0.02	A	0.40	0.26-0.59	1.30E-06	0.36	0.20-0.62	4.30E-05	0.38	0.24-0.58	1.00E-06	0.33	0.18-0.59	2.50E-05
rs6079536	20	14644881	<i>MACROD2</i>	0.44	A	0.73	0.65-0.83	8.50E-06	0.64	0.54-0.75	1.60E-06	0.72	0.63-0.82	9.50E-06	0.60	0.50-0.72	5.10E-07
rs6079537	20	14645385	<i>MACROD2</i>	0.49	G	1.32	1.17-1.49	5.40E-05	1.52	1.29-1.79	6.00E-06	1.38	1.21-1.57	1.40E-05	1.64	1.38-1.96	5.10E-07
rs6079540	20	14653887	<i>MACROD2</i>	0.5	A	0.75	0.66-0.84	2.90E-05	0.65	0.55-0.77	3.70E-06	0.73	0.64-0.83	2.20E-05	0.62	0.52-0.73	1.10E-06
rs6079544	20	14662456	<i>MACROD2</i>	0.49	A	1.35	1.20-1.53	1.30E-05	1.57	1.33-1.84	1.20E-06	1.41	1.24-1.60	3.60E-06	1.67	1.40-1.99	2.10E-07
rs6074787	20	14671008	<i>MACROD2</i>	0.49	A	1.33	1.18-1.50	3.40E-05	1.53	1.30-1.80	4.10E-06	1.38	1.21-1.57	1.30E-05	1.62	1.36-1.93	8.70E-07
rs10446030	20	14675385	<i>MACROD2</i>	0.49	G	1.34	1.19-1.52	2.20E-05	1.54	1.30-1.81	3.20E-06	1.39	1.22-1.58	7.40E-06	1.63	1.37-1.95	6.80E-07
rs6079553	20	14680605	<i>MACROD2</i>	0.49	A	1.35	1.19-1.52	1.70E-05	1.55	1.31-1.82	2.10E-06	1.40	1.23-1.60	4.10E-06	1.66	1.39-1.97	3.00E-07
rs4814324	20	14690829	<i>MACROD2</i>	0.49	A	1.36	1.20-1.54	1.10E-05	1.58	1.34-1.86	9.80E-07	1.41	1.24-1.61	3.90E-06	1.67	1.40-2.00	2.00E-07
rs4141463	20	14695470	<i>MACROD2</i>	0.43	A	0.75	0.66-0.85	4.30E-05	0.62	0.52-0.73	5.50E-07	0.71	0.62-0.81	5.80E-06	0.56	0.47-0.67	2.10E-08
rs6074798	20	14709709	<i>MACROD2</i>	0.48	A	1.38	1.22-1.56	4.80E-06	1.56	1.32-1.84	2.10E-06	1.43	1.26-1.63	1.20E-06	1.65	1.39-1.97	4.40E-07
rs980319	20	14724939	<i>MACROD2</i>	0.48	G	1.36	1.20-1.54	1.00E-05	1.52	1.29-1.79	5.10E-06	1.41	1.24-1.61	3.00E-06	1.61	1.35-1.92	1.00E-06

Supplementary Table 3. Summary of top association signals from exploratory analyses across Discovery and Replication data. Reporting restricted to SNPs that meet primary analyses association signal at $P < 5 \times 10^{-6}$.

SNP	Chr	Position	Gene	MAF	Minor	Diagnosis	AGP Discovery			AGRE			Combined		
							OR	95%CI	P	OR	95%CI	P	OR	95%CI	P
rs2196826	1	240612956	<i>PLD5</i>	0.305	A	Spc All Vrb	0.58	0.33-0.69	1.1E-08	0.89	0.43-1.07	2.7E-01	0.71	0.39-0.81	1.1E-06
rs2580237	1	240619604	<i>PLD5</i>	0.48	G	Spc All Vrb	1.52	1.3-1.78	2.5E-06	1.00	0.83-1.19	9.2E-01	1.26	1.12-1.42	5.2E-04
rs11809951	1	240621154	<i>PLD5</i>	0.32	G	Spc All Vrb	0.64	0.54-0.75	8.0E-07	0.92	0.76-1.1	3.8E-01	0.75	0.66-0.85	2.6E-05
rs2654862	1	240621187	<i>PLD5</i>	0.48	G	Spc All Vrb	1.52	1.3-1.78	2.3E-06	1.00	0.83-1.19	9.2E-01	1.26	1.12-1.42	4.9E-04
rs2580222	1	240625569	<i>PLD5</i>	0.41	C	Spc All Vrb	0.65	0.56-0.76	2.0E-06	0.97	0.81-1.15	7.5E-01	0.78	0.69-0.88	2.5E-04
rs2809985	1	240629344	<i>PLD5</i>	0.39	G	Spc All Vrb	0.65	0.56-0.77	2.5E-06	0.97	0.82-1.16	8.0E-01	0.78	0.7-0.88	2.6E-04
rs9461347	6	27384557	<i>POM121L2</i>	0.04	A	Spc All Vrb	2.61	1.71-4.09	4.4E-06	1.48	0.89-2.51	1.1E-01	1.97	1.42-2.74	2.5E-05
rs11155089	6	140220670	<i>LOC100132735</i>	0.27	A	Spc All Vrb	0.64	0.53-0.75	2.1E-06	0.98	0.8-1.2	8.6E-01	0.77	0.67-0.87	2.0E-04
rs11624358	14	46563202	<i>MDGA2</i>	0.19	A	Spc All Vrb	0.63	0.53-0.76	4.5E-06	0.94	0.76-1.16	5.6E-01	0.76	0.66-0.87	1.8E-04
rs3784730	15	90788132	<i>ST8SIA2</i>	0.43	G	Spc All Vrb	1.58	1.35-1.86	4.0E-07	1.36	1.14-1.64	1.6E-03	1.47	1.31-1.66	1.1E-08
rs2045268	15	90790651	<i>ST8SIA2</i>	0.40	A	Spc All Vrb	1.56	1.32-1.83	1.5E-06	1.32	0.92-1.89	1.5E-01	1.51	1.3-1.76	1.4E-06
rs4284229	1	38622891	-	0.15	G	Spc Al Nvrb	2.12	1.57-2.89	1.1E-06	1.16	0.85-1.58	3.6E-01	1.60	1.29-1.99	2.6E-05
rs16848148	2	212851861	<i>ERBB4</i>	0.05	G	Spc Al Nvrb	3.60	2-6.87	1.3E-06	0.86	0.52-1.43	5.3E-01	1.65	1.15-2.38	3.7E-03
rs10258862	7	39083323	<i>POU6F2</i>	0.33	G	Spc Al Nvrb	1.95	1.54-2.49	4.4E-07	0.73	0.56-0.95	2.3E-02	1.23	1.04-1.46	3.0E-02
rs1404999	7	39087990	<i>POU6F2</i>	0.33	A	Spc Al Nvrb	1.90	1.49-2.42	1.5E-06	0.72	0.55-0.94	1.9E-02	1.20	1.01-1.43	5.2E-02
rs12864778	13	72858013	-	0.46	A	Spc Al Nvrb	0.54	0.43-0.68	2.1E-06	1.03	0.79-1.33	8.6E-01	0.72	0.61-0.86	6.9E-04

Supplementary Table 3, continued.

SNP	Chr	Position	Gene	MAF	Minor	Diagnosis	AGP + SAGE			AGP + AGRE + SAGE		
							OR	95%CI	P	OR	95%CI	P
rs2196826	1	240612956	<i>PLD5</i>	0.305	A	Spc All Vrb	1.37	1.20-1.57	2.5E-06	1.26	1.13-1.39	1.2E-05
rs2580237	1	240619604	<i>PLD5</i>	0.48	G	Spc All Vrb	1.29	1.14-1.45	3.1E-05	1.16	1.06-1.28	1.9E-03
rs11809951	1	240621154	<i>PLD5</i>	0.32	G	Spc All Vrb	0.77	0.68-0.88	7.2E-05	0.83	0.75-0.91	1.9E-04
rs2654862	1	240621187	<i>PLD5</i>	0.48	G	Spc All Vrb	1.28	1.14-1.44	3.8E-05	1.16	1.06-1.28	1.8E-03
rs2580222	1	240625569	<i>PLD5</i>	0.41	C	Spc All Vrb	0.79	0.70-0.90	1.7E-04	0.86	0.78-0.94	1.2E-03
rs2809985	1	240629344	<i>PLD5</i>	0.39	G	Spc All Vrb	0.80	0.71-0.90	2.5E-04	0.86	0.78-0.94	1.3E-03
rs9461347	6	27384557	<i>POM121L2</i>	0.04	A	Spc All Vrb	0.52	0.38-0.72	6.3E-05	0.58	0.44-0.76	8.2E-05
rs11155089	6	140220670	<i>LOC100132735</i>	0.27	A	Spc All Vrb	1.33	1.16-1.52	2.9E-05	1.21	1.09-1.35	4.5E-04
rs11624358	14	46563202	<i>MDGA2</i>	0.19	A	Spc All Vrb	1.37	1.17-1.60	6.4E-05	1.24	1.10-1.40	5.9E-04
rs3784730	15	90788132	<i>ST8SIA2</i>	0.43	G	Spc All Vrb	1.30	1.15-1.47	2.2E-05	1.26	1.14-1.38	2.0E-06
rs2045268	15	90790651	<i>ST8SIA2</i>	0.40	A	Spc All Vrb	0.78	0.69-0.88	6.3E-05	0.78	0.69-0.88	2.9E-05
rs4284229	1	38622891	-	0.15	G	Spc Al Nvrb	1.65	1.31-2.08	2.3E-05	1.51	1.26-1.80	4.8E-06
rs16848148	2	212851861	<i>ERBB4</i>	0.05	G	Spc Al Nvrb	2.09	1.42-3.08	2.3E-04	1.42	1.05-1.93	2.4E-02
rs10258862	7	39083323	<i>POU6F2</i>	0.33	G	Spc Al Nvrb	1.54	1.28-1.85	5.1E-06	1.14	0.99-1.31	7.0E-02
rs1404999	7	39087990	<i>POU6F2</i>	0.33	A	Spc Al Nvrb	0.66	0.55-0.80	1.1E-05	0.89	0.77-1.02	1.0E-01
rs12864778	13	72858013	-	0.46	A	Spc Al Nvrb	1.44	1.21-1.71	3.6E-05	1.23	1.08-1.41	2.1E-03

Supplementary Table 4. Summary of top association signals from exploratory analyses across Discovery and Replication data. Reporting restricted to SNPs that meet primary analyses association signal at $P < 5 \times 10^{-6}$ for parent of origin.

SNP	Chr	Position	Gene	MAF	Minor	Diagnosis	AGP Discovery			AGRE			Combined		
							OR	95%CI	P	OR	95%CI	P	OR	95%CI	P
rs9532931	13	41298079	KIAA0564	0.08	G	Spc Eur Mat	0.46	0.34-0.63	1.7E-07	0.63	0.42-0.93	4.0E-03	0.52	0.41-0.67	5.2E-09
rs7329533	13	41456003		0.05	A	Spc Eur Mat	0.40	0.26-0.59	9.7E-07	0.88	0.55-1.4	5.1E-01	0.55	0.41-0.74	1.3E-05
rs1475531	20	14815422	MACROD2	0.36	C	Spc Eur Mat	1.62	1.33-1.99	7.7E-07	1.02	0.79-1.31	8.8E-01	1.36	1.17-1.6	2.8E-05
rs11155089	6	140220670	LOC100132735	0.27	A	Spc Eur Pat	0.62	0.51-0.76	2.3E-06	1.05	0.81-1.37	6.5E-01	0.75	0.64-0.89	2.1E-04
rs10258862	7	39083323	POU6F2	0.33	G	Spc Eur Pat	1.63	1.33-2.01	1.3E-06	0.79	0.61-1.02	3.0E-02	1.23	1.05-1.44	6.5E-03
rs1404999	7	39087990	POU6F2	0.33	A	Spc Eur Pat	1.62	1.32-2	1.8E-06	0.79	0.61-1.02	3.6E-02	1.23	1.05-1.44	6.5E-03
rs205409	16	27971449	GSG1L	0.43	G	Spc Eur Pat	0.64	0.53-0.77	1.6E-06	1.23	0.98-1.56	3.5E-02	0.83	0.72-0.96	7.6E-03
rs9348512	6	10564692	-	0.33	A	Str Eur Mat	0.55	0.42-0.71	2.6E-06	0.84	0.62-1.15	2.1E-01	0.65	0.53-0.79	4.3E-06
rs9532931	13	41298079	KIAA0564	0.08	G	Str Eur Mat	0.39	0.26-0.57	3.1E-07	0.57	0.35-0.93	5.1E-03	0.45	0.33-0.62	1.3E-08
rs6074798	20	14709710	MACROD2	0.48	A	Str Eur Mat	1.79	1.38-2.34	4.5E-06	0.99	0.73-1.33	9.3E-01	1.42	1.17-1.73	1.4E-04
rs1475531	20	14815422	MACROD2	0.36	C	Str Eur Mat	1.84	1.41-2.4	1.9E-06	1.18	0.85-1.63	2.4E-01	1.54	1.25-1.89	7.2E-06
rs4836231	5	122124002	-	0.36	G	Str Eur Pat	0.55	0.42-0.71	2.7E-06	0.86	0.63-1.17	2.7E-01	0.66	0.54-0.81	1.4E-05
rs28603112	5	122126587	-	0.36	C	Str Eur Pat	0.55	0.42-0.71	2.7E-06	0.86	0.63-1.17	2.7E-01	0.66	0.54-0.81	1.4E-05
rs1363614	5	122176254	SNX2	0.36	G	Str Eur Pat	0.55	0.42-0.72	4.5E-06	0.86	0.63-1.17	2.7E-01	0.67	0.55-0.82	2.3E-05
rs8065403	17	31487436	-	0.17	A	Str Eur Pat	0.50	0.36-0.68	3.6E-06	0.72	0.5-1.02	2.5E-02	0.59	0.46-0.74	1.0E-06
rs4141463	20	14695471	MACROD2	0.43	A	Str Eur Pat	0.54	0.42-0.7	8.6E-07	0.94	0.69-1.27	6.2E-01	0.67	0.55-0.82	1.4E-05
rs11675023	2	140382810	-	0.20	G	Spc All Mat	0.61	0.49-0.75	2.2E-06	1.02	0.81-1.29	8.4E-01	0.78	0.66-0.91	7.0E-04
rs11677529	2	140406237	-	0.20	A	Spc All Mat	0.61	0.49-0.76	3.3E-06	1.02	0.81-1.29	8.4E-01	0.78	0.67-0.92	9.1E-04
rs1475531	20	14815422	MACROD2	0.36	C	Spc All Mat	1.59	1.32-1.91	4.9E-07	0.99	0.8-1.23	9.5E-01	1.31	1.14-1.51	4.7E-05
rs3817118	4	77418235	LOC100129583	0.10	C	Spc All Pat	2.02	1.48-2.78	3.2E-06	1.03	0.77-1.37	8.0E-01	1.38	1.12-1.7	7.9E-04
rs10258862	7	39083323	POU6F2	0.33	G	Spc All Pat	1.56	1.28-1.89	3.0E-06	0.78	0.63-0.97	9.5E-03	1.15	1-1.33	4.0E-02
rs7297890	12	115694448	TMEM118	0.10	G	Spc All Pat	0.54	0.41-0.71	4.1E-06	0.87	0.65-1.16	2.5E-01	0.69	0.56-0.84	3.2E-05
rs10006242	4	176783314	-	0.40	A	Str All Mat	1.73	1.36-2.22	3.0E-06	1.02	0.79-1.32	8.3E-01	1.36	1.14-1.62	2.4E-04
rs9348512	6	10564692	-	0.33	A	Str All Mat	0.57	0.45-0.74	4.3E-06	0.87	0.67-1.14	2.4E-01	0.70	0.58-0.84	2.9E-05
rs6557675	8	23396491	-	0.31	A	Str All Mat	0.54	0.41-0.69	5.2E-07	0.99	0.76-1.29	9.4E-01	0.72	0.6-0.87	1.3E-04
rs10507103	12	97887773	ANKS1B	0.17	G	Str All Mat	2.02	1.47-2.8	4.7E-06	1.27	0.9-1.81	1.0E-01	1.61	1.27-2.04	1.3E-05
rs9532931	13	41298079	KIAA0564	0.08	G	Str All Mat	0.45	0.31-0.65	5.0E-06	0.58	0.38-0.87	1.2E-03	0.50	0.38-0.66	2.6E-08
rs4807188	19	1926217	CSNK1G2	0.02	A	Str All Mat	12.00	2.98-104.76	2.8E-06	2.33	0.53-13.98	1.5E-01	5.80	2.22-19.2	8.3E-06
rs6077999	20	10923285	-	0.30	G	Str All Mat	0.57	0.44-0.73	3.6E-06	0.84	0.64-1.09	1.3E-01	0.68	0.56-0.81	7.7E-06
rs1475531	20	14815422	MACROD2	0.36	C	Str All Mat	1.77	1.39-2.26	1.6E-06	1.11	0.84-1.46	4.0E-01	1.44	1.2-1.73	2.0E-05
rs10006242	4	176783314	-	0.40	A	Str All Mat	1.73	1.36-2.22	3.0E-06	1.02	0.79-1.32	8.3E-01	1.36	1.14-1.62	2.4E-04
rs4836231	5	122124002	-	0.36	G	Str All Pat	0.56	0.44-0.73	3.2E-06	0.91	0.71-1.18	4.3E-01	0.71	0.59-0.85	5.6E-05
rs28603112	5	122126587	-	0.36	C	Str All Pat	0.56	0.44-0.73	3.2E-06	0.91	0.71-1.18	4.3E-01	0.71	0.59-0.85	5.6E-05
rs2125903	17	45890913	ACSF2	0.26	A	Str All Pat	1.76	1.37-2.27	4.9E-06	1.23	0.95-1.6	6.1E-02	1.46	1.21-1.75	1.1E-05

Supplementary Table 5. Candidate genes identified from previous association studies. Results from candidate genes culled from the literature, selected because they show evidence for association from GWA studies or from multiple candidate gene studies [z-score (*P*-value)]. Presented is the SNP within each gene showing the strongest association (smallest *p*-value) for each of the four primary analyses. Negative z-score indicates the minor allele is under-transmitted.

Gene	SNP	MAF	Spc All	Str All	Spc Eur	Str Eur
<i>SLC6A4</i>	rs11657536	0.024	-1.69 (0.095)	-2.32 (0.020)	-1.92 (0.055)	-2.63 (0.011)
<i>AVPR1A</i>	rs11174810	0.027	-0.56 (0.578)	-1.53 (0.125)	-0.89 (0.376)	-0.89 (0.371)
<i>EN2</i>	rs1861958	0.122	0.49 (0.624)	0.86 (0.388)	0.29 (0.769)	0.40 (0.689)
<i>RELN</i>	rs39334	0.373	-3.897 (9.7·10 ⁻⁵)	-2.34 (0.019)	-3.61 (3.1·10 ⁻⁴)	-1.57 (0.116)
<i>SLC25A12</i>	rs908670	0.288	4.107 (4.0·10 ⁻⁵)	2.34 (0.019)	4.15 (3.4·10 ⁻⁵)	2.53 (0.011)
<i>MET</i>	rs2237712	0.047	-2.35 (0.019)	-2.55 (0.011)	-1.79 (0.074)	-2.17 (0.030)
<i>GABRB3</i>	rs7172653	0.45	2.37 (0.018)	1.00 (0.316)	2.48 (0.013)	0.86 (0.393)
<i>OXTR</i>	rs2301261	0.103	-2.42 (0.016)	-1.54 (0.124)	-2.69 (0.007)	-1.78 (0.075)
<i>ITGB3</i>	rs2056131	0.305	-2.07 (0.039)	-1.71 (0.087)	-2.08 (0.038)	-2.02 (0.043)
<i>CNTNAP2</i>	rs929353	0.321	2.31 (0.021)	2.84 (0.004)	3.09 (0.002)	4.07 (4.6·10 ⁻⁵)
<i>GRIK2</i>	rs17828670	0.109	-1.25 (0.211)	-2.46 (0.014)	-1.25 (0.210)	-2.54 (0.011)
<i>CDH9</i>	rs12652586	0.165	-1.22 (0.223)	-0.04 (0.970)	-1.46 (0.146)	-0.19 (0.848)
<i>CDH10</i>	rs16893429	0.03	-2.59 (0.012)	-1.53 (0.127)	-2.43 (0.015)	-0.95 (0.344)
<i>SEMA5A</i>	rs415024	0.285	-2.33 (0.020)	-3.04 (0.002)	-2.12 (0.034)	-3.10 (0.002)
<i>GABRA4</i>	rs1512130	0.358	2.33 (0.020)	2.93 (0.003)	2.19 (0.029)	2.57 (0.010)
<i>GABRB1</i>	rs4694846	0.423	3.21 (0.001)	1.35 (0.177)	3.35 (8.1·10 ⁻⁴)	2.00 (0.045)
<i>ITGA4</i>	rs1449259	0.109	2.43 (0.015)	1.70 (0.090)	2.81 (0.005)	2.08 (0.038)

Table 6a. Family-based association results by SNP and sites contributing samples for comparison to Wang et al. (PMID: 19404256). SNPs presented were found to be associated with risk for autism in the previous study. Cells contain z-score, *P*-value, relative allele frequency. For column 3, N is sample size in trios, P is *P*-value, Z is the z-statistics for biased transmission and f is the allele frequency for a selected allele. Fst is Wright's measure of differentiation computed across the sites.

SNP	F _{st}		ALL	AGRE ¹	IMGSAC	Miami ¹	Canagen	Paris	CPEA ¹	Ireland	Portugal
		N	1217	53	224	108	290	118	63	131	213
rs7704904	0.0019	P	0.953	0.668	0.444	0.178	0.724	0.472	0.793	0.927	0.254
		Z	0.059	-0.429	-0.765	1.347	-0.354	-0.718	0.263	0.092	1.140
		f	0.640	0.648	0.624	0.636	0.630	0.619	0.698	0.649	0.659
rs1896731	0.0051	P	0.458	0.354	0.315	0.026	0.106	0.567	0.310	0.843	0.421
		Z	0.742	0.926	1.001	-2.223	1.616	0.572	1.016	-0.198	-0.804
		f	0.637	0.630	0.677	0.603	0.637	0.673	0.611	0.660	0.587
rs10038113	0.0047	P	0.460	0.631	0.362	0.010	0.141	0.787	0.352	0.795	0.889
		Z	0.739	0.480	0.911	-2.578	1.471	0.271	0.930	0.260	-0.140
		f	0.582	0.571	0.621	0.559	0.585	0.627	0.547	0.583	0.534
rs12518194	0.0022	P	0.929	0.777	0.586	0.110	0.637	0.660	0.793	0.710	0.639
		Z	0.089	-0.283	-0.544	1.600	-0.471	-0.440	0.263	0.371	0.469
		f	0.646	0.651	0.624	0.651	0.635	0.627	0.705	0.652	0.669
rs4307059	0.0020	P	0.739	0.777	0.779	0.131	0.760	0.531	0.500	0.925	0.314
		Z	0.333	-0.283	-0.280	1.508	-0.306	-0.626	0.674	-0.094	1.006
		f	0.648	0.652	0.627	0.652	0.637	0.632	0.707	0.653	0.669
rs4327572	0.0020	P	1.000	0.668	0.494	0.113	0.603	0.660	0.896	0.859	0.440
		Z	0.000	0.429	0.684	-1.584	0.520	0.440	-0.130	-0.178	-0.772
		f	0.355	0.352	0.376	0.349	0.368	0.371	0.302	0.350	0.330

1) Families from these sites overlap somewhat with those in Wang et al. (111 trios) Note that 943 families from the AGRE repository were genotyped in Wang et al, but only a small subset of those families are contained in the data reported here. The most substantial overlap is for the Miami families: 108 families were reported on here, whereas 487 families from the Miami group were analyzed in (Wang PMID: 19404256).

Table 6b. Family-based association results by sites contributing samples for comparison to Weiss et al. (PMID: 19812673). The SNP in the table is in perfect or almost perfect linkage disequilibrium with the SNP P is *P*-value, Z is the z-statistics for biased transmission and f is the allele frequency for a selected allele. Fst is Wright's measure of differentiation computed across the sites.

SNP	F _{st}		ALL	AGRE ²	IMGSAC	Miami	Canagen	Paris	CPEA	Ireland	Portugal
		N	1217	53	224	108	290	118	63	131	213
rs2234235	0.0014	P	0.160	0.480	0.433	0.297	0.020	0.491	0.705	0.763	1.000
		Z	1.406	0.707	0.784	-1.043	2.333	0.688	0.378	0.302	0.000
		f	0.034	0.035	0.035	0.042	0.031	0.040	0.023	0.022	0.042

2) Families from this site overlap somewhat with those in Weiss et al. (106 trios) (Weiss PMID: 19812673).

Supplementary Figure 4. Power curves by sample size (N, panels), allele frequency and allelic odds ratio (lines). Power was calculated for the binary trait (ASD, yes/no) under the assumption that the risk locus is the genotyped SNP, a log additive model, the population prevalence is 0.005, and the rejection region is $P = 5 \cdot 10^{-8}$. The colored lines map to different allelic odds ratios: black = 1.2, grey = 1.4, red = 1.6, blue = 1.8 and green = 2.0.

